(Registration number 2000/012469/07)

# Financial statements for the year ended 31 March 2025

These financial statements have been audited in compliance with the applicable requirements of the Companies Act of South Africa. Issued 21 May 2025

### **General Information**

Country of incorporation and domicile	South Africa
Nature of business and principal activities	Registration of and trading in pharmaceutical products
Directors	I.F. Oliver P. Godha
Holding company	Unichem Laboratories Ltd incorporated in India
Auditors	GNR Auditors Chartered Accountants (SA) Registered Auditors
Company registration number	2000/012469/07
Level of assurance	These financial statements have been audited in compliance with the applicable requirements of the Companies Act of South Africa.
Preparer	The financial statements were independently compiled by: RMC Auditors

### Index

The reports and statements set out below comprise the financial statements presented to the shareholder:

	Page
Directors' Responsibilities and Approval	3
Directors' Report	6
Independent Auditor's Report	4 - 5
Statement of Financial Position	7
Statement of Profit or Loss and Other Comprehensive Income	8
Statement of Changes in Equity	9
Statement of Cash Flows	10
Accounting Policies	11 <del>-</del> 15
Notes to the Financial Statements	16 <b>-</b> 27
Shareholder Information	
The following supplementary information does not form part of the financial statements and is unaudited:	
Detailed Income Statement	28
Preparer	

**RMC** Auditors

### Published

21 May 2025

(Registration number 2000/012469/07) Financial Statements for the year ended 31 March 2025

### **Directors' Responsibilities and Approval**

The directors are required in terms of the Companies Act of South Africa to maintain adequate accounting records and are responsible for the content and integrity of the financial statements and related financial information included in this report. It is their responsibility to ensure that the financial statements fairly present the state of affairs of the company as at the end of the financial year and the results of its operations and cash flows for the period then ended, in conformity with International Financial Reporting Standards. The external auditors are engaged to express an independent opInion on the financial statements.

The financial statements are prepared in accordance with International Financial Reporting Standards and are based upon appropriate accounting policies consistently applied and supported by reasonable and prudent judgements and estimates.

The directors acknowledge that they are ultimately responsible for the system of internal financial control established by the company and place considerable importance on maintaining a strong control environment. To enable the directors to meet these responsibilities, the board sets standards for internal control aimed at reducing the risk of error or loss in a cost effective manner. The standards include the proper delegation of responsibilities within a clearly defined framework, effective accounting procedures and adequate segregation of duties to ensure an acceptable level of risk. These controls are monitored throughout the company and all employees are required to maintain the highest ethical standards in ensuring the company's business is conducted in a manner that in all reasonable circumstances is above reproach. The focus of risk management in the company is on identifying, assessing, managing and monitoring all known forms of risk across the company. While operating risk cannot be fully eliminated, the company endeavours to minimise it by ensuring that appropriate infrastructure, controls, systems and ethical hehaviour are applied and managed within predetermined procedures and constraints.

The directors are of the opinion, based on the information and explanations given by management, that the system of internal control provides reasonable assurance that the financial records may be relied on for the preparation of the financial statements. However, any system of internal financial control can provide only reasonable, and not absolute, assurance against material misstatement or loss.

The directors have reviewed the company's cash flow forecast for the year to 31 March 2026 and, in light of this review and the current financial position, they are satisfied that the company has or had access to adequate resources to continue in operational existence for the foreseeable future.

The external auditors are responsible for independently auditing and reporting on the company's financial statements. The financial statements have been examined by the company's external auditors and their report is presented on pages 4 to 5.

The financial statements set out on pages 7 to 28, which have been prepared on the going concern basis, were approved by the board on 21 May 2025 and were signed on their behalf by:

Approval of financial statements

I.F. Oliver

21 May 2025



O18 293 2726
 O18 462 8039 (Klerksdorp)
 O18 293 2753
 O18 462 8245 (Klerksdorp)
 E-mail: admin@gnrauditors.co.za
 E-mail: klerksdorp@gnrauditors.co.za

Peter Mokaba Avenue 86 Potchefstroom 2531

$\succ$	20395
Nool	rdbrug
	2522

### **Independent Auditor's Report**

#### To the Shareholder of Unichem SA (Pty) Ltd

#### Opinion

We have audited the financial statements of Unichem SA (Pty) Ltd (the company) set out on pages 7 to 27, which comprise the statement of financial position as at 31 March 2025; and the statement of profit or loss and other comprehensive income; the statement of changes in equity; and the statement of cash flows for the year then ended; and notes to the financial statements, including material accounting policy information.

In our opinion, the financial statements present fairly, in all material respects, the financial position of Unichem SA (Pty) Ltd as at 31 March 2025, and its financial performance and cash flows for the year then ended, in accordance with International Financial Reporting Standards and the requirements of the Companies Act of South Africa.

#### **Basis for Opinion**

We conducted our audit in accordance with International Standards on Auditing. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the company in accordance with the Independent Regulatory Board for Auditors' Code of Professional Conduct for Registered Auditors (IRBA Code) and other independence requirements applicable to performing audits of financial statements in South Africa. We have fulfilled our other ethical responsibilities in accordance with the IRBA Code and in accordance with other ethical requirements applicable to performing sections of the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards). We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter	How our audit addressed the key audit matter	
Completeness of revenue		
Management issues a revenue invoice for all products purchased from Unichem Laboratories Limited and landed in South Africa.	We obtained a purchase listing from management and confirmed the listing with Unichem Laboratories Limited, thus confirming the completeness of purchases.	
Unichem SA (Pty) Ltd's trading model is to only import products that		
are ordered by their customers and not to hold inventory, except if there is an unfinished transaction over a period end.	For a sample of purchases, including transactions near year end, we ensured that the products have been cleared as arrived in South Africa by the Customs Authority and have been sold to a	
Such imported products are then sold to customers upon landing in South Africa and completion of analytical testing.	customer in South Africa.	
	Based on our work performed we come to the same conclusion	
Management concluded that all products landed and cleared have been sold at year end.	as management.	

### Independent Auditor's Report

#### Other Information

The directors are responsible for the other information. The other information comprises the information included in the document titled "Unichem SA (Pty) Ltd financial statements for the year ended 31 March 2025", which includes the Directors' Report as required by the Companies Act of South Africa and the supplementary information as set out on page 28. The other information does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express an audit opinion or any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

#### Responsibilities of the Directors for the Financial Statements

The directors are responsible for the preparation and fair presentation of the financial statements in accordance with International Financial Reporting Standards and the requirements of the Companies Act of South Africa, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with International Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with International Standards on Auditing, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and
  perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a
  basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from
  error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the
  financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

GNA Auditors M Rademeyer (CA) SA Partner Chartered Accountants (SA) Registered Auditors

21 May 2025 Potchefstroom

A Rademeyer, AL Nel, CR Rademeyer, M Rademeyer PR903681

(Registration number 2000/012469/07) Financial Statements for the year ended 31 March 2025

### **Directors' Report**

The directors have pleasure in submitting their report on the financial statements of Unichem SA (Pty) Ltd for the year ended 31 March 2025.

### 1. Review of financial results and activities

The financial statements have been prepared in accordance with International Financial Reporting Standards and the requirements of the Companies Act of South Africa. The accounting policies have been applied consistently compared to the prior year.

Full details of the financial position, results of operations and cash flows of the company are set out in these financial statements.

### 2. Share capital

Authorised			2025 Number of	2024 shares
Ordinary shares			250,000	250,000
	2025	2024	2025	2024
ssued	R	R	Number of	shares
Ordinary shares	190,000	190,000	190,000	190,000

There have been no changes to the authorised or issued share capital during the year under review.

### 3. Directorate

The directors in office at the date of this report are as follows:

Directors	Nationality
I.F. Oliver	South Africa
P. Godha	ndia

There have been no changes to the directorate for the year under review.

### 4. Holding company

The company's holding company is Unichem Laboratories Ltd which holds 100% (2024: 100%) of the company's equity. Unichem Laboratories Ltd is incorporated in India.

### 5. Events after the reporting period

The directors are not aware of any material event which occurred after the reporting date and up to the date of this report.

### 6. Auditors

GNR Auditors continued in office as auditors for the company for 2025.

### 7. Statement of disclosure to the company's auditors

With respect to each person who is a director on the day that this report is approved:

- there is, so far as the person is aware, no relevant audit information of which the company's auditors are unaware; and
- the person has taken all the steps that he/she ought to have taken as a director to be aware of any relevant audit information and to establish that the company's auditors are aware of that information.

### Statement of Financial Position as at 31 March 2025

	Note(s)	2025 R	2024 R
Assets			
Non-Current Assets			
Property, plant and equipment	2	147	8,111
Right-of-use assets	3	335,555	503,332
Deferred tax	4	394,708	340,185
		730,410	851,628
Current Assets			
Inventories	5	4,774,483	2,512,977
Trade and other receivables	6	8,773,600	7,088,892
Cash and cash equivalents		3,921,619	4,235,019
		17,469,702	13,836,888
Total Assets		18,200,112	14,688,516
Equity and Liabilities			
Equity			
Share capita	7	190,000	190,000
Retained income		5,947,356	6,094,770
		6,137,356	6,284,770
Liabilities			
Non-Current Liabilities			
Finance lease liabilities	3	163,677	381,351
Current Liabilities			
Trade and other payables	8	11,685,749	7,856,884
Finance lease liabilities	3	213,330	165,511
		11,899,079	8,022,395
Total Liabilities		12,062,756	8,403,746
Total Equity and Liabilities		18,200,112	14,688,516

### Statement of Profit or Loss and Other Comprehensive Income

	Note(s)	2025 R	2024 R
Revenue	9	28,862,079	23,055,452
Cost of sales		(23,744,637)	(19,800,995)
Gross profit		5,117,442	3,254,457
Other operating income	10	-	50,000
Other operating expenses		(5,279,569)	(4,513,940)
Operating (loss) profit	11	(162,127)	(1,209,483)
Investment income		-	2,414
Finance costs	14	(39,811)	(52,875)
(Loss) profit before taxation		(201,938)	(1,259,944)
Taxation	15	54,523	340,185
(Loss) profit for the year		(147,415)	(919,759)
Other comprehensive income		-	-
Total comprehensive (loss) income for the year		(147,415)	(919,759)

## **Statement of Changes in Equity**

	Share capita	Retained income	Total equity
	R	R	R
Balance at 01 April 2023	190,000	7,014,529	7,204,529
Loss for the year Other comprehensive income	-	(919,759) -	(919,759) -
Total comprehensive Loss for the year	-	(919,759)	(919,759)
Balance at 01 April 2024	190,000	6,094,771	6,284,771
Loss for the year Other comprehensive income	-	(147,415) -	(147,415) -
Total comprehensive Loss for the year	•	(147,415)	(147,415)
Balance at 31 March 2025	190,000	5,947,356	6,137,356
Note(s)	7		

### **Statement of Cash Flows**

		2025	2024
	Note(s)	R	R
Cash flows from operating activities			
Cash receipts from customers		27,187,389	19,810,777
Cash paid to suppliers and employees		(27,291,123)	(21,943,124)
Cash used in operations	16	(103,734)	(2,132,347)
Interest income		-	2,414
Finance costs	14	-	-
Tax paid	17	-	63,258
Net cash from operating activities		(103,734)	(2,066,675)
Cash flows from investing activities			
Cash flows from financing activities			
Cash repayments on lease liabilities	3	(209,666)	(202,503)
Total cash movement for the year		(313,400)	(2,269,178)
Cash and cash equivalents at the beginning of the year		4,235,019	6,504,197
Cash and cash equivalents at the end of the year		3,921,619	4,235,019

(Registration number 2000/012469/07) Financial Statements for the year ended 31 March 2025

### **Accounting Policies**

### 1. Material accounting policies

Management has considered the principles of materiality in IFRS Practice Statement 2 Making Materiality Judgements, and only those accounting policies which are considered material have been presented in these financial statements.

### 1.1 Basis of preparation

The financial statements have been prepared on the going concern basis in accordance with, and in compliance with, International Financial Reporting Standards ("IFRS") and International Financial Reporting Standards Interpretations Committee ("IFRS IC") interpretations issued and effective at the time of preparing these financial statements and the Companies Act of South Africa as amended.

The financial statements comply with the requirements of the SAICA Financial Reporting Guides as issued by the Accounting Practices Committee and the Financial Reporting Pronouncements as issued by the Financial Reporting Standards Council.

The financial statements have been prepared on the historic cost convention, unless otherwise stated in the accounting policies which follow and incorporate the material accounting policies set out below. They are presented in Rands, which is the company's functional currency.

These accounting policies are consistent with the previous period.

### **1.2** Property, plant and equipment

Property, plant and equipment is initially measured at cost.

Expenditure incurred subsequently for major services, additions to or replacements of parts of property, plant and equipment are capitalised if it is probable that future economic benefits associated with the expenditure will flow to the company and the cost can be measured reliably. Day to day servicing costs are included in profit or loss in the year in which they are incurred.

Property, plant and equipment is subsequently stated at cost less accumulated depreciation and impairment losses except for land which is not depreciated.

The useful lives of items of property, plant and equipment have been assessed as follows:

Item	Depreciation method	Average useful life
Office equipment	Straight line	5 years
IT equipment	Straight line	3 years

The residual value, useful life and depreciation method of each asset are reviewed at the end of each reporting period. No material changes were made.

There were no indicators of impairment for property, plant and equipment and no impairment tests were performed.

### **1.3** Financial instruments

Financial instruments are recognised when the company becomes a party to the contractual provisions. They are measured, at initial recognition, at fair value plus transaction costs, if any.

All regular way purchases or sales of financial assets are recognised and derecognised on a trade date basis.

The material accounting policies for each type of financial instrument held by the company are presented below:

(Registration number 2000/012469/07) Financial Statements for the year ended 31 March 2025

### Accounting Policies

### Financial instruments (continued)

### Trade and other receivables

Trade and other receivables, excluding, when applicable, VAT and prepayments, are measured, subsequent to initial recognition, at amortised cost.

The amortised cost is the amount recognised on the receivable initially, minus principal repayments, plus cumulative amortisation (interest) using the effective interest method of any difference between the initial amount and the maturity amount, adjusted for any loss allowance.

The accounting policy for impairment of trade and other receivables is set out in the loss allowances and write offs accounting policy.

### Trade and other payables

Trade and other payables, excluding VAT and amounts received in advance, are classified as financial liabilities subsequently measured at amortised cost.

### Cash and cash equivalents

Cash and cash equivalents are stated at carrying amount which is deemed to be fair value.

### Derecognition

The company derecognises a financial asset only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. If the company neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the company recognises its retained interest in the asset and an associated liability for amounts it may have to pay. If the company retains substantially all the risks and rewards of ownership of a transferred financial asset, the company continues to recognise the financial asset and also recognises a collateralised borrowing for the proceeds received.

The company derecognises financial liabilities when its obligations are discharged, cancelled or they expire. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognised in profit or loss.

### 1.4 Tax

### Current tax assets and liabilities

Current tax for current and prior periods is, to the extent unpaid, recognised as a liability. If the amount already paid in respect of current and prior periods exceeds the amount due for those periods, the excess is recognised as an asset.

Current tax liabilities (assets) for the current and prior periods are measured at the amount expected to be paid to (recovered from) the tax authorities, using the tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

(Registration number 2000/012469/07) Financial Statements for the year ended 31 March 2025

### Accounting Policies

### 1.4 Tax (continued)

### Deferred tax assets and liabilities

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the tax base used for taxation purposes.

A deferred tax liability is recognised for all taxable temporary differences.

A deferred tax asset is recognised for all deductible temporary differences to the extent that it is probable that taxable profit will be available against which the deductible temporary difference can be utilised.

A deferred tax asset is recognised for the carry forward of unused tax losses to the extent that it is probable that future taxable profit will be available against which they can be utilised.

When management assess the extent to which is it probable that taxable profit will be available against which potential deferred tax assets can be utilised, they take into consideration that the utilisation of assessed losses are limited to the greater of 80% of the taxable income or R1 million in the year of assessment.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The deferred tax rate applied to assets is determined by the expected manner of recovery. Where the expected recovery of the asset is through sale, the capital gains tax rate is applied. The normal tax rate is applied when the expected recovery is through use. A combination of these rates is applied if the recovery is expected to be partly through use and sale.

Deferred tax assets are reviewed at each reporting date and are reduced if it is no longer probable that the related tax benefit will be realised. Such reductions are reversed when the probability of future taxable profits improves. The review by management has not resulted in the reduction of the deferred tax assets.

### Tax expenses

The income tax expense consists of current and deferred tax and is recognised in profit or loss.

### 1.5 Leases

The company assesses whether a contract is, or contains a lease, at the inception of the contract.

No contracts were identified that required specific judgement as to whether they contained leases.

(Registration number 2000/012469/07) Financial Statements for the year ended 31 March 2025

### **Accounting Policies**

### 1.5 Leases (continued)

#### Company as lessee

A lease liability and corresponding right-of-use asset are recognised at the lease commencement date, for all lease agreements for which the company is a lessee, except for short-term leases of 12 months or less, or leases of low value assets. For these leases, the company recognises the lease payments as an operating expense on a straight-line basis over the term of the lease.

A lease of an asset is considered low value if it is under R 100,000.

#### Lease liability

Lease liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease.

The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect lease payments made. Interest charged on the lease liability is included in finance costs.

#### Right-of-use assets

Right-of-use assets are presented as a separate line item on the Statement of Financial Position.

They are measured initially at the initial amount of the lease liability plus upfront payments and initial direct costs.

Right-of-use assets are subsequently measured at cost less accumulated depreciation and impairment losses.

Right-of-use assets are depreciated, from commencement date, over the shorter period of lease term and useful life of the underlying asset.

The useful lives of right-of-use assets are presented in the following table:

Item	Depreciation method	Average useful life
Buildings	Straight line	5 years

The residual value, useful life and depreciation method of each asset are reviewed at the end of each reporting period. No material changes were made.

### 1.6 Inventories

Inventories are measured at the lower of cost and net realisable value on the first-in-first-out basis.

The cost of inventories comprises of all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.

Write downs and reversals of write downs of inventories are included as part of the cost of goods sold.

### **1.7 Impairment of assets**

Management assesses, at the end of each reporting period, whether there is any indication that an asset may be impaired. If any such indication exists, then the recoverable amount of the asset is determined.

The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use. If the recoverable amount cannot be determined for an individual asset, then it is determined for the cash generating unit to which the asset belongs.

An impairment loss is recognised for an asset (or a cash-generating unit) if the recoverable amount of the asset or cash generating unit is less than the carrying amount. The impairment loss is determined as the difference between the two amounts. For cash generating units, the impairment loss is allocated to the assets on a pro-rata basis.

(Registration number 2000/012469/07) Financial Statements for the year ended 31 March 2025

### **Accounting Policies**

### **1.7 Impairment of assets (continued)**

Impairment losses are recognised immediately in profit or loss.

### 1.8 Share capital and equity

Equity instruments issued by the company are recognised at the proceeds received, net of direct issue costs.

### **1.9 Employee benefits**

#### Short-term employee benefits

Short-term employee benefits, which consist of salaries and fees, are recognised in the period in which the service is rendered and are not discounted.

The expected cost of compensated absences is recognised as an expense as the employees render services that increase their entitlement or, in the case of non-accumulating absences, when the absence occurs.

The expected cost of profit sharing and bonus payments is recognised as an expense when there is a legal obligation to make such payments as a result of past performance.

### **1.10** Revenue from contracts with customers

The company recognises revenue from the following major sources:

Sales of pharmaceutical goods - wholesale

Revenue is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties. The company recognises revenue when it transfers control of a product or service to a customer.

### 1.11 Cost of sales

When inventories are sold, the carrying amount of those inventories is recognised as an expense in the period in which the related revenue is recognised. The amount of any write-down of inventories to net realisable value and all losses of inventories are recognised as an expense in the period the write-down or loss occurs. The amount of any reversal of any write-down of inventories, arising from an increase in net realisable value, is recognised as a reduction in the amount of inventories recognised as an expense in the period in which the reversal occurs.

The related cost of providing services recognised as revenue in the current period is included in cost of sales.

Cost of sales is reduced by the amount recognised in inventory as a "right to returned goods asset" which represents the company's right to recover products from customers where customers exercise their right of return under the company returns policy.

### 1.12 Translation of foreign currencies

#### Foreign currency transactions

A foreign currency transaction is recorded, on initial recognition in Rands, by applying to the foreign currency amount the spot exchange rate between the functional currency and the foreign currency at the date of the transaction.

Foreign currency monetary items are translated at the end of the reporting period using the closing rate.

Cash flows arising from transactions in a foreign currency are recorded in Rands by applying to the foreign currency amount the exchange rate between the Rand and the foreign currency at the date of the cash flow.

Refer to the individual accounting policies for financial instruments for the detailed foreign exchange accounting policies.

### 1.13 Statement of Cash Flows

The statement of cash flows is presented using the indirect method.

### Notes to the Financial Statements

		2025 R	2024 R
--	--	-----------	-----------

### 2. Property, plant and equipment

	2025			2024		
	Cost or revaluation	Accumulated ( depreciation	Carrying value	Cost or revaluation	Accumulated ( depreciation	Carrying value
Furniture and fixtures	2,870	(2,726)	144	2,870	(2,152)	718
Office equipment	21,240	(21,240)	-	21,240	(21,240)	-
IT equipment	31,146	(31,143)	3	31,146	(23,753)	7,393
Total	55,256	(55,109)	147	55,256	(47,145)	8,111

(Registration number 2000/012469/07) Financial Statements for the year ended 31 March 2025

### Notes to the Financial Statements

2025 2024 R R
------------------

### 2. Property, plant and equipment (continued)

### Reconciliation of property, plant and equipment - 2025

	Opening balance	Depreciation	Total
Furniture and fixtures	718	(574)	144
IT equipment	7,393	(7,390)	3
	8,111	(7,964)	147

### Reconciliation of property, plant and equipment - 2024

	Opening balance	Depreciation	Tota
Furniture and fixtures	1,292	(574)	718
IT equipment	14,783	(7,390)	7,393
	16,075	(7,964)	8,111

### 3. Leases (company as lessee)

Details pertaining to leasing arrangements, where the company is lessee are presented below:

	2025				2024	
	Cost or revaluation	Accumulated depreciation	Carrying value	Cost or revaluation	Accumulated depreciation	Carrying value
Buildings	335,555	=	335,555	503,332	-	503,332

### Notes to the Financial Statements

	2025 R	2024 R
3. Leases (company as lessee) (continued)		
Net carrying amounts of right-of-use assets		
The carrying amounts of right-of-use assets are included in the following line items:		
Buildings	335,555	503,332
Depreciation recognised on right-of-use assets		
Depreciation recognised on each class of right-of-use assets, is presented below. It includes c expensed in the total depreciation charge in profit or loss (note 11), as well as depreciation wh cost of other assets.		
Buildings	167,777	167,777
Other disclosures		
Interest expense on lease liabilities	39,811	52,875
Finance lease liabilities		
The maturity analysis of lease liabilities is as follows:		
Within one year Two to five years	221,227 251,723	210,693 472,950
Less finance charges component	472,950 (95,943)	683,643 (136,781
	377,007	546,862
Non-current liabilities Current liabilities	163,677 213,330	381,351 165,511
	377,007	546,862
4. Deferred tax		
Deferred tax asset		
Tax losses available for set off against future taxable income	394,708	340,185
Total deferred tax asset	394,708	340,185
The deferred tax assets and the deferred tax liability relate to income tax in the same jurisdiction settlement. Therefore, they have been offset in the statement of financial position as follows:	on, and the <b>l</b> aw allow	/s net
Deferred tax asset	394,708	340,185
Reconciliation of deferred tax asset / (liability)		
At beginning of year Increases (decrease) in tax loss available for set off against future taxable income - gross of valuation allowance	340,185 54,523	- 340,185
3.000 0. 12120.001 0.000		

394,708

340,185

(Registration number 2000/012469/07) Financial Statements for the year ended 31 March 2025

### Notes to the Financial Statements

	2025 R	2024 R
5. Inventories		
Finished goods	4,774,483	2,512,977
6. Trade and other receivables		
Financial instruments: Trade receivables Deposits	8,772,930 670	6,421,367 670
Non-financial instruments: VAT	-	666,855
Total trade and other receivables	8,773,600	7,088,892
Split between non-current and current portions		
Current assets	8,773,600	7,088,892
Financial instrument and non-financial instrument components of trade and	other receivables	
At amortised cost Non-financial instruments	8,773,600 -	6,422,037 666,855
	8,773,600	7,088,892

### Trade and other receivables pledged as security

No trade and other receivables are pledged as security.

### Exposure to credit risk

Trade receivables inherently expose the company to credit risk, being the risk that the company will incur financial loss if customers fail to make payments as they fall due.

The company's historical credit loss experience does not show significantly different loss patterns for different customer segments. The provision for credit losses is therefore based on past due status without disaggregating into further risk profiles. The loss allowance provision is determined as follows:

	2025	2025	2024	2024
Aging of trade receivables (undisputed, considered good - Unsecured)	Gross carrying amount	Loss allowance (Lifetime expected credit loss)	Gross carrying amount	Loss allowance (Lifetime expected credit loss)
Not due	7,433,892	-	4,069,290	-
Less than 6 months due	1,339,038	-	2,352,077	-
Total	8,772,930	-	6,421,367	-

### Exposure to currency risk

The net carrying amounts, in Rand, of trade and other receivables, excluding non-financial instruments, are denominated in the following currencies. The amounts have been presented in Rand by converting the foreign currency amount at the closing rate at the reporting date.

(Registration number 2000/012469/07) Financial Statements for the year ended 31 March 2025

### Notes to the Financial Statements

				2025 R	2024 R
6. Trade	and other receivables (continued)				
<b>Rand Amo</b> Rand	unt			8,773,600	6,422,037
7. Share	e capital				
Authorised Ordinary sh				250,000	250,000
	<b>tion of number of shares issued:</b> s at 01 Apri <b>l</b> 2024			190,000	190,000
<b>lssued</b> Ordinary				190,000	190,000
Shares he	d by promotors at the end of the year:				
Sr. no 4 5	Promotor name Unichem Laboratories Limited Unichem Laboratories Limited	No. of shares 13000 6000	% of total shares 68.42% 31.58%	Change from 2024 0 0	
8. Trade	and other payables				
Trade paya Accrued au	ıdit fees			11,630,032 45,700	7,818,384 38,500
Non-finance VAT	cial instruments:			10,017	-

### Exposure to currency risk

The net carrying amounts, in Rand, of trade and other payables, excluding non-financial instruments, are denominated in the following currencies. The amounts have been presented in Rand by converting the foreign currency amount at the closing rate at the reporting date.

Rand Amount Rand	11,675,731	7,856,883
9. Revenue		
Revenue from contracts with customers Sale of pharmaceutical goods	28,862,079	23,055,452

(Registration number 2000/012469/07) Financial Statements for the year ended 31 March 2025

### Notes to the Financial Statements

	2025 R	2024 R
9. Revenue (continued)		
Disaggregation of revenue from contracts with customers		
The company disaggregates revenue from customers as follows:		
Sale of goods Sale of pharmaceutical goods	28,862,079	23,055,452
Timing of revenue recognition		
At a point in time Sale of goods	28,862,079	23,055,452
<b>Country</b> South Africa	28,862,079	23,055,452
<b>Customer</b> Trinity Pharma (Pty) Ltd Unimed (Pty) Ltd Other not making up 10% or more of sa <b>l</b> es	20,059,671 7,219,888 1,582,520	13,249,608 9,425,901 379,943
	28,862,079	23,055,452
10. Other operating income		
Site audit	-	50,000
<ul><li><b>11. Operating profit (loss)</b></li><li>Operating (loss) profit for the year is stated after charging (crediting) the following, amongst othe</li></ul>	ers:	
Auditor's remuneration - external Audit fees	50,300	37,000
Remuneration, other than to employees Consulting and professional services	5,000	9,475
Employee costs		
Salaries, wages, bonuses and other benefits	333,900	333,900
<b>Depreciation and amortisation</b> Depreciation of property, plant and equipment Depreciation of right-of-use assets	7,964 167,777	7,964 167,777
Total depreciation and amortisation	175,741	175,741

### Expenses by nature

The total cost of sales, selling and distribution expenses, marketing expenses, general and administrative expenses, research and development expenses, maintenance expenses and other operating expenses are analysed by nature as follows:

### Notes to the Financial Statements

	2025	2024
	R	R
11. Operating profit (loss) (continued)		
Changes in inventories of finished goods and work in progress	23,744,637 333,900	19,800,995 333,900
Emp <b>l</b> oyee costs Depreciation, amortisation and impairment	175,741	175,741
Other expenses	4,769,928	4,004,299
	29,024,206	24,314,935
2. Employee costs		
Employee costs Basic	333,900	333,900
13. Depreciation, amortisation and impairment losses		
Depreciation		
Property, plant and equipment Right-of-use assets	7,964 167,777	7,964 167,777
	175,741	175,741
	,	
14. Finance costs		
Lease liabilities	39,811	52,875
15. Taxation		
Major components of the tax expense (income)		
<b>Deferred</b> Arising from tax <b>l</b> oss	(54,523)	(340,185
16. Cash used in operations	(04,020)	(0-10,100
Profit (loss) before taxation	(201,938)	(1,259,944
Adjustments for non-cash items: Depreciation, amortisation, impairments and reversals of impairments	175,741	175,741
Adjust for items which are presented separately: Interest income	_	(2,414
Finance costs	39,811	52,875
Changes in working capital: (Increase) decrease in inventories	(2,261,506)	(2,512,977
Increase) decrease in trade and other receivables ncrease (decrease) in trade and other payables	(1,684,708) 3,828,866	(3,294,675 4,709,047
	(103,734)	(2,132,347
17. Tax paid		
Balance at beginning of the year	-	63,258

### 18. Contingencies

There are no contingent commitments of the company.

### Notes to the Financial Statements

	2025 R	2024 R
19. Related parties		
<b>Relationships</b> Holding company Members of key management	Unichem Laboratories Ltd IF Oliver	
Related party balances		
Amounts included in Trade receivable (Trade Payable) regarding re Unichem India Limited Unichem India Limited	elated parties (11,311,667) 73,721	(7,153,367) 109,065
Related party transactions		
<b>Purchases from (sales to) related parties</b> Unichem Laboratories Limited Unichem Laboratories Limited	26,075,863 (563,825)	22,313,972 (512,983)
Compensation to directors and other key management Short-term employee benefits	333,900	333,900

Unichem SA (Pty) Ltd (Registration number 2000/012469/07) Financial Statements for the year ended 31 March 2025			
Notes to the Financial Statements			
Figures in Rand		2025	2024
20. Financial instruments and risk management			
Categories of financial instruments			
Categories of financial assets			
2025			
	Note(s)	Amortised	Total
Trade and other receivables Cash and cash equivalents	9	<b>6031</b> 8,773,600 3,921,619	8,773,600 3,921,619
		12,695,219	12,695,219
2024			
	Note(s)	Note(s) Amortised	Total
Trade and other receivables Cash and cash equivalents	Q	6,422,037 4,235,019	6,422,037 4,235,019
		10,657,056	10,657,056

(Registration number 2000/012469/07) Financial Statements for the year ended 31 March 2025

### Notes to the Financial Statements

	2025 R	2024 R
· · · · · · · · · · · · · · · · · · ·		

### 20. Financial instruments and risk management (continued)

### Categories of financial liabilities

2025

	Note(s)	Amortised cost	Leases	Tota
Trade and other payables Finance lease obligations	8 3	11,675,731 -	_ 377,007	11,675,731 377,007
		11,675,731	377,007	12,052,738
2024				
	Note(s)	Amortised cost	Leases	Tota
Trade and other payables Finance lease obligations	8 3	7,856,883 -	- 546,862	7,856,883 546,862
		7,856,883	546,862	8,403,745

### Capital risk management

The company's objective when managing capital (which includes share capital, borrowings, working capital and cash and cash equivalents) is to maintain a flexible capital structure that reduces the cost of capital to an acceptable level of risk and to safeguard the company's ability to continue as a going concern while taking advantage of strategic opportunities in order to maximise stakeholder returns sustainably.

Finance lease liabilities Trade and other payables	377,007 8 11,685,748	,
Total borrowings	12,062,755	6 8,403,745
Cash and cash equivalents	(3,921,619)	(4,235,019)
Net borrowings	8,141,136	4,168,726
Equity	6,137,356	6,284,771
Gearing ratio	133 %	66 %

(Registration number 2000/012469/07) Financial Statements for the year ended 31 March 2025

### Notes to the Financial Statements

2025 R	2024 R

### 20. Financial instruments and risk management (continued)

### Financial risk management

### Overview

The company is exposed to the following risks from its use of financial instruments:

- Credit risk;
- Liquidity risk; and
- Market risk (currency risk, interest rate risk and price risk).

### Credit risk

Credit risk is the risk of financial loss to the company if a customer or counterparty to a financial instrument fails to meet its contractual obligations.

The maximum exposure to credit risk is presented in the table below:

(Registration number 2000/012469/07) Financial Statements for the year ended 31 March 2025

### Notes to the Financial Statements

2025	2024
R	R

### 20. Financial instruments and risk management (continued)

		2025		2024			
		Gross carrying amount	Credit loss allowance	Amortised cost / fair value	Gross carrying amount	Credit loss allowance	Amortised cost / fair value
Trade and other receivables Cash and cash equivalents	6	8,773,600 3,921,619	-	8,773,600 3,921,619	7,088,892 4,235,019	-	7,088,892 4,235,019
		12,695,219	-	12,695,219	11,323,911	-	11,323,911

### Liquidity risk

The maturity profile of contractual cash flows of non-derivative financial liabilities, and financial assets held to mitigate the risk, are presented in the following table. The cash flows are undiscounted contractual amounts.

#### 2025

		Carrying amount
Non-current liabilities Finance lease liabilities		163,677
<b>Current liabilities</b> Trade and other payables Finance lease liabilities	8 3	11,675,731 213,330
		(12,052,738)
2024		
		Carrying amount
Non-current liabilities Finance lease liabilities		381,351
<b>Current liabilities</b> Trade and other payables Finance lease liabilities	8	7,856,883 165,511
		(8,403,745)

### **Detailed Income Statement**

	Note(s)	2025 R	2024 R
Pevenue			
Revenue Sale of goods		28,862,079	23,055,452
Cost of sales			
Opening stock		(2,512,977)	-
Purchases		(26,006,143)	(22,313,972)
Closing stock		4,774,483	2,512,977
		(23,744,637)	(19,800,995)
Gross profit		5,117,442	3,254,457
Other operating income Other income		_	50,000
			<u> </u>
Other operating expenses			
Auditor's remuneration - external audit	11	(50,300)	(37,000)
Bank charges		(13,156)	(13,671)
Consulting and professional fees - accounting		(5,000)	(7,775)
Consulting and professional fees - other		=	(1,700)
Depreciation		(175,741)	(175,741)
Employee costs		(333,900)	(333,900)
Medicine Control Council		(3,800)	(1,900)
Annual fees		(17,590)	(17,266)
Low value rental		(4,400)	(70.054)
Pharmaceutical testing		(55,655)	(76,951)
Pharmaceutical regulatory Medical expenses		(1,998,839)	(1,950,975)
Municipal expenses		(237) (25,217)	(20,870)
Repairs and maintenance		(23,217) (2,170)	(20,070)
Security		(4,749)	(4,697)
Subscriptions		(2,317)	(7,227)
Telephone and fax		(2,228)	(2,133)
Training		(8,499)	(2,435)
Transport and freight		(2,575,771)	(1,859,699)
		(5,279,569)	(4,513,940)
Operating (loss) profit	11	(162,127)	(1,209,483)
Investment income		-	2,414
Finance costs	14	(39,811)	(52,875)
(Loss) profit before taxation		(201,938)	(1,259,944)
Taxation	15	54,523	340,185
(Loss) profit for the year		(147,415)	(919,759)